Rare Disease Treatment, Targeting FDA 'Breakthrough Therapy' for U.S. Launch in 2027

Larimar Therapeutics, Inc. (NASDAQ: LRMR) announced on March 19, 2026—alongside its fourth-quarter and full-year 2025 financial results—that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to nomlabofusp, its investigational treatment for Friedreich’s ataxia. The company said it has reached agreement with the FDA on a Biologics License Application (BLA) strategy that employs frataxin as a novel surrogate endpoint, as well as on the design of a global Phase 3 confirmatory trial. Larimar now plans to submit its BLA in June 2026 and to launch nomlabofusp in the U.S. in the first half of 2027.

In February, Larimar completed a $115 million registered direct offering, bolstering its year-end cash position to approximately $244.5 million (about KRW 330 billion) and securing a cash runway through the second quarter of 2027.

With the Breakthrough Therapy designation officially announced, Larimar expects to begin global Phase 3 trial screening in Q2 2026 and to administer the first patient dose by mid-2026. The news triggered a sharp, short-term rise in the company’s share price, underscoring strong market interest.

Larimar Therapeutics is a clinical-stage biotech leveraging cell-penetrating peptide technology to develop protein replacement therapies. Its lead candidate, nomlabofusp, is a recombinant fusion protein designed to deliver frataxin directly to the mitochondria of patients with Friedreich’s ataxia. This progressive rare neurodegenerative disorder—characterized by cerebellar ataxia and cardiomyopathy—has very limited approved treatment options, making competition in new drug development and regulatory review outcomes a focal point in the industry.